<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871247</url>
  </required_header>
  <id_info>
    <org_study_id>40398</org_study_id>
    <nct_id>NCT00871247</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of Actavis Group&#xD;
      hf, Iceland, finasteride and Merck &amp; Co. Inc., U.S.A. (Proscar), finasteride, administered as&#xD;
      a 1 x 5 mg tablet, under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.&#xD;
&#xD;
      Official Title: Randomized, 2-Way Crossover, Bioequivalence Study of Finasteride 5 mg Tablet&#xD;
      and Proscar Administered as 1 x 5 mg Tablet in Healthy Subjects Under Fed Conditions&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finasteride 5 mg single dose tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proscar® 5 mg Tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride 5 mg Tablet, single dose</intervention_name>
    <description>A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Finasteride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proscar® 5 mg Tablet, single dose</intervention_name>
    <description>B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Finasteride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, smoker or non-smoker, 18 years of age and older.&#xD;
&#xD;
          -  Capable of consent.&#xD;
&#xD;
          -  BMI ~19.0 and &lt;30.0 kg/m2 Sexual abstinence for the duration of the study is&#xD;
             recommended given the potential harm to a fetus from migration of this drug to the&#xD;
             semen. Sexually-active males must refrain from heterosexual intercourse without the&#xD;
             use of a condom for a period of one week from the initial dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HN at screening.&#xD;
&#xD;
          -  EeG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          -  History of significant alcohol abuse or drug abuse within one year prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Regular use of alcohol within six months prior to the screening visit (more than&#xD;
             fourteen units of alcohol per week [I Unit:= 150 mL of wine, 360 mL of beer, or 45 mL&#xD;
             of 40% alcohol]).&#xD;
&#xD;
          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or&#xD;
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the&#xD;
             screening visit or positive urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to heparin, finasteride, or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication .&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (incl~ding natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day.&#xD;
&#xD;
          -  Any food alIergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
          -  50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
          -  301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen)&#xD;
             within 7 days prior to administration of the study medication.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G 1 V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>finasteride</keyword>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

